Like this bit: A recent study used the technology to conjugate recombinant Spike RBD of selected SARS-CoV-2 variants. It sought to understand the impact of COVID-19 vaccination on the levels of neutralizing antibodies against these RBD variants, and demonstrated thatthe nanosized molecular glue approach to bioconjugation provides a rapid and effective tool for SARS-CoV-2 multiplex immunoassay development for vaccine study (1).
ADO Price at posting:
31.5¢ Sentiment: Buy Disclosure: Held
